华仁药业
(300110)
| 流通市值：31.43亿 | | | 总市值：31.45亿 |
| 流通股本：11.81亿 | | | 总股本：11.82亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 873,969,132.95 | 605,047,701.2 | 309,965,165.17 | 1,321,454,092.38 |
| 营业收入 | 873,969,132.95 | 605,047,701.2 | 309,965,165.17 | 1,321,454,092.38 |
| 二、营业总成本 | 828,714,628.7 | 561,308,128.71 | 289,559,960.82 | 1,204,460,892.77 |
| 营业成本 | 597,750,521.71 | 407,643,479.72 | 206,903,941.21 | 831,915,880.14 |
| 税金及附加 | 15,481,530.74 | 10,706,395.2 | 5,534,190.7 | 21,663,256.87 |
| 销售费用 | 77,499,624.04 | 54,665,065.83 | 30,631,620.5 | 150,362,677.61 |
| 管理费用 | 62,823,194.96 | 39,021,204.52 | 22,786,352.76 | 90,393,682.15 |
| 研发费用 | 48,276,037.85 | 30,015,569.19 | 14,080,034.45 | 67,825,661.63 |
| 财务费用 | 26,883,719.4 | 19,256,414.25 | 9,623,821.2 | 42,299,734.37 |
| 其中:利息费用 | 26,553,047.66 | 18,787,729.97 | 9,356,759.36 | 41,969,585.59 |
| 其中:利息收入 | 688,248.95 | 156,903.28 | 53,030.79 | 523,301.92 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 3,368,955.86 | 377,296.31 | -44,283.19 | 4,815,796.52 |
| 资产处置收益 | - | - | 0 | 7,332.49 |
| 资产减值损失(新) | -4,506,355.53 | -4,367,812.95 | 9,557.52 | -563,219,531.8 |
| 信用减值损失(新) | -4,480,260.27 | -4,518,981.63 | 546,574.58 | -22,904,890.73 |
| 其他收益 | 5,769,738.71 | 4,517,940.61 | 1,989,472.94 | 8,612,828.1 |
| 四、营业利润 | 45,406,583.02 | 39,748,014.83 | 22,906,526.2 | -455,695,265.81 |
| 加:营业外收入 | 224,091.05 | 181,477.65 | 46,753.14 | 2,568,119.11 |
| 减:营业外支出 | 2,536,070.37 | 986,301.31 | 2,873,983.48 | 5,814,169.1 |
| 五、利润总额 | 43,094,603.7 | 38,943,191.17 | 20,079,295.86 | -458,941,315.8 |
| 减:所得税费用 | 13,490,428.25 | 8,533,042.71 | 3,275,886.86 | 447,760 |
| 六、净利润 | 29,604,175.45 | 30,410,148.46 | 16,803,409 | -459,389,075.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 29,604,175.45 | 30,410,148.46 | 16,803,409 | -459,389,075.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 26,914,695.91 | 28,542,412.07 | 15,958,601.73 | -462,900,017.63 |
| 少数股东损益 | 2,689,479.54 | 1,867,736.39 | 844,807.27 | 3,510,941.83 |
| 扣除非经常损益后的净利润 | 22,565,554.12 | 25,450,329.57 | 16,512,325.85 | -470,281,564.11 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.02 | 0.01 | -0.39 |
| (二)稀释每股收益 | 0.02 | 0.02 | 0.01 | -0.39 |
| 九、综合收益总额 | 29,604,175.45 | 30,410,148.46 | 16,803,409 | -459,389,075.8 |
| 归属于母公司股东的综合收益总额 | 26,914,695.91 | 28,542,412.07 | 15,958,601.73 | -462,900,017.63 |
| 归属于少数股东的综合收益总额 | 2,689,479.54 | 1,867,736.39 | 844,807.27 | 3,510,941.83 |
| 公告日期 | 2026-10-28 | 2026-08-27 | 2026-04-24 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |